In addition, anifrolumab ameliorates overall lupus activity with a larger effect on both low and high IFN-I signature groups and was able to maintain the low IFN signature status in these 2 groups based on the MUSE trial (43). Here, IFNA1 is linked to systemic lupus erythematosus.